News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Pharmacokinetics, Safety and Tolerability of Olaparib and Temozolomide for Recurrent Glioblastoma: Results of the Phase I OPARATIC Trial

Al's Comment:

 There are 2 important points from this study:

1. They tested a rat model to see if olaparib can cross the blood brain barrier. This is a standard test that is used for most drugs.  They found that this drug does not cross the blood brain barrier in rats.  Then they tested in people by giving the drug before a surgery and testing the tumor sample removed and found that 100% of the time it does cross the blood brain barrier and gets into the human brain.   This shows that we really can't trust the mouse models for BBB penetration and we need these human tests.

2. Olaparib is a PARP inhibitor (which is approved for other types of cancer so it is readily available off label) and they found that in the test tube it acts as a radiation sensitizer at the concentrations they found in the human testing of tumor samples. They report 36% of patients with recurrent glioblastoma were progression free at 6 months, which shows it has some effect and needs to be studied further to see how best to use it!

 


Posted on: 04/30/2020

Pharmacokinetics, Safety and Tolerability of Olaparib and Temozolomide for Recurrent Glioblastoma: Results of the Phase I OPARATIC Trial

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740